{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:39:17Z","timestamp":1793230757157,"version":"4.5.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1681\/asn.2013121312","type":"journal-article","created":{"date-parts":[[2014,7,4]],"date-time":"2014-07-04T00:23:02Z","timestamp":1404433382000},"page":"39-47","source":"Crossref","is-referenced-by-count":113,"title":["Tolvaptan plus Pasireotide Shows Enhanced Efficacy in a PKD1 Model"],"prefix":"10.1681","volume":"26","author":[{"given":"Katharina","family":"Hopp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Hommerding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-9-20230208","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease.","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"R3-9-20230208","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells.","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat Genet"},{"key":"R4-9-20230208","first-page":"F956","article-title":"Effects of calcium on the vasopressin-sensitive cAMP metabolism in medullary tubules.","volume":"249","author":"Kusano","year":"1985","journal-title":"Am J Physiol"},{"key":"R5-9-20230208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1620\/tjem.193.207","article-title":"Nephron distribution of total low Km cyclic AMP phosphodiesterase in mouse, rat and rabbit kidney.","volume":"193","author":"Kusano","year":"2001","journal-title":"Tohoku J Exp Med"},{"key":"R6-9-20230208","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0898-6568(99)00031-5","article-title":"Functional properties of Ca2+-inhibitable type 5 and type 6 adenylyl cyclases and role of Ca2+ increase in the inhibition of intracellular cAMP content.","volume":"11","author":"Chabard\u00e8s","year":"1999","journal-title":"Cell Signal"},{"key":"R7-9-20230208","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","article-title":"Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease.","volume":"30","author":"Yamaguchi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"R8-9-20230208","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"R9-9-20230208","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: Insights into pathogenesis, ciliary abnormalities, and common features with human disease.","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R10-9-20230208","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.2008.111","article-title":"A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5\u2032 end of Pkd1.","volume":"73","author":"Starremans","year":"2008","journal-title":"Kidney Int"},{"key":"R11-9-20230208","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI64313","article-title":"Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.","volume":"122","author":"Hopp","year":"2012","journal-title":"J Clin Invest"},{"key":"R12-9-20230208","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway.","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int"},{"key":"R13-9-20230208","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells.","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R14-9-20230208","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R15-9-20230208","doi-asserted-by":"crossref","first-page":"19264","DOI":"10.1074\/jbc.271.32.19264","article-title":"Localization of mRNAs encoding Ca2+-inhibitable adenylyl cyclases along the renal tubule. Functional consequences for regulation of the cAMP content.","volume":"271","author":"Chabard\u00e8s","year":"1996","journal-title":"J Biol Chem"},{"key":"R16-9-20230208","doi-asserted-by":"crossref","first-page":"F859","DOI":"10.1152\/ajprenal.00109.2009","article-title":"Characterization of vasopressin-responsive collecting duct adenylyl cyclases in the mouse.","volume":"298","author":"Strait","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"R17-9-20230208","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1681\/ASN.2010040409","article-title":"Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla.","volume":"21","author":"Rieg","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R18-9-20230208","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","article-title":"Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.","volume":"24","author":"Gattone","year":"1999","journal-title":"Dev Genet"},{"key":"R19-9-20230208","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"R20-9-20230208","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R21-9-20230208","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R22-9-20230208","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: Three years\u2019 experience.","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-9-20230208","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"R24-9-20230208","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0014-5793(86)81180-2","article-title":"Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells.","volume":"198","author":"Friedlander","year":"1986","journal-title":"FEBS Lett"},{"key":"R25-9-20230208","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.1988.31","article-title":"Reversal of somatostatin inhibition of AVP-induced cAMP by pertussis toxin.","volume":"33","author":"Ishikawa","year":"1988","journal-title":"Kidney Int"},{"key":"R26-9-20230208","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate.","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"R27-9-20230208","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"R28-9-20230208","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"R29-9-20230208","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial.","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"R30-9-20230208","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R31-9-20230208","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial.","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"R32-9-20230208","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1985.tb00212.x","article-title":"Somatostatin and water excretion in man: an intrarenal action.","volume":"23","author":"Walker","year":"1985","journal-title":"Clin Endocrinol (Oxf"},{"key":"R33-9-20230208","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1136\/bmj.292.6537.1701","article-title":"Effect of somatostatin on renal function.","volume":"292","author":"Vora","year":"1986","journal-title":"Br Med J (Clin Res Ed"},{"key":"R34-9-20230208","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/gut.2003.036053","article-title":"Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.","volume":"53","author":"Reynaert","year":"2004","journal-title":"Gut"},{"key":"R35-9-20230208","first-page":"1380","article-title":"Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells.","volume":"25","author":"Liu","year":"2004","journal-title":"Acta Pharmacol Sin"},{"key":"R36-9-20230208","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R37-9-20230208","doi-asserted-by":"crossref","first-page":"F1089","DOI":"10.1152\/ajprenal.00242.2012","article-title":"Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.","volume":"303","author":"Wang","year":"2012","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201501000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:24:38Z","timestamp":1786130678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201501000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2013121312","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}